Department of Korean Obstetrics and Gynecology, College of Korean Medicine, Semyung University, Jecheon 27136, Republic of Korea.
R&D Center, Hecto Healthcare Co., Ltd., Seoul 06142, Republic of Korea.
Nutrients. 2024 Jun 23;16(13):1993. doi: 10.3390/nu16131993.
BN-202M is derived from humans and consists of two strains, BEPC22 and BELP53. Body fat reduction effect and safety of BN-202M were assessed in overweight participants. A total of 150 participants were randomly assigned to the BN-202M and placebo groups at a 1:1 ratio. Dual-energy X-ray absorptiometry was used to objectively measure body fat. After 12 weeks of oral administration, the body fat percentage (-0.10 ± 1.32% vs. 0.48 ± 1.10%; = 0.009) and body fat mass (-0.24 ± 1.19 kg vs. 0.23 ± 1.05 kg; = 0.023) of the BN-202M group decreased significantly compared to those of the placebo group. The body weight (-0.58 kg, = 0.004) and body mass index (BMI; -0.23, = 0.003) was found to decrease significantly at 12 weeks in the BN-202M group, but not in the placebo group. Metabolome analysis revealed that β-alanine, 3-aminoisobutyric acid, glutamic acid, and octopamine decreased in the weight-decreased BN-202M post-intake group. In the gut microbiota analysis, Akkermansia showed a statistically significant increase in the BN-202M group post-intake compared to the placebo group. No serious adverse events were observed in either group. These results suggest that BN-202M is safe and effective for reducing body fat and weight.
BN-202M 源自人类，由两个株系，BEPC22 和 BELP53 组成。超重参与者评估了 BN-202M 的减脂效果和安全性。共 150 名参与者以 1:1 的比例随机分配至 BN-202M 组和安慰剂组。双能 X 射线吸收法用于客观测量体脂。口服给药 12 周后，BN-202M 组的体脂百分比（-0.10±1.32%比 0.48±1.10%； = 0.009）和体脂量（-0.24±1.19kg 比 0.23±1.05kg； = 0.023）与安慰剂组相比显著下降。与安慰剂组相比，12 周时 BN-202M 组的体重（-0.58kg， = 0.004）和体重指数（BMI；-0.23， = 0.003）显著下降。代谢组学分析显示，β-丙氨酸、3-氨基异丁酸、谷氨酸和章鱼胺在 BN-202M 摄入后体重减轻的组中减少。在肠道微生物组分析中，与安慰剂组相比，BN-202M 组摄入后 Akkermansia 显著增加。两组均未观察到严重不良事件。这些结果表明，BN-202M 安全且有效，可用于减少体脂和体重。
